Items Tagged ‘Stage IV/Recurrent Esophageal Cancer’

August 25th, 2015

Patients Rising, Launched to Fight for Access to Vital Therapies and Services for Patients with Life-Threatening Diseases

By

Patient advocacy veterans Jonathan and Terry Wilcox today announced the launch of a new not-for-profit organization, Patients Rising. This patient advocacy organization will educate, advocate and communicate the importance of access to vital therapies and services for patients who face life-changing and life-threatening diseases. The organization will be focused on ensuring that the patients’ voice […]

View full entry

Tags: All Cancer Types, Esophageal Cancer, News, Stage IV/Recurrent Esophageal Cancer, Types of Cancer, vital options


February 12th, 2015

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers

By

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase. These inhibitors may have therapeutic application in the treatment of various types of […]

View full entry

Tags: AMG 337, Esophageal Cancer, esophagus, Gastric Cancer, gastroesophageal junction, Gastrointestinal Cancer, GI tumors, MET inhibitor, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


December 4th, 2014

Esophageal Cancer Survival Improved Using Targeted Therapy Developed in Lung Cancer

By

Targeted therapy commonly used in lung cancer improves survival of esophageal cancer patients according to clinical trial results recently presented at the National Cancer Research Institute (NCRI) Cancer Conference in the UK. The esophagus is a muscular tube that food and liquids pass through on their on their way to the stomach. Each year in the […]

View full entry

Tags: EGFR, Esophageal Cancer, iressa, News, Stage IV/Recurrent Esophageal Cancer


November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


April 3rd, 2013

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer

By

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. The esophagus is a muscular tube that food and liquids pass through on their on their way to the stomach. Each year in […]

View full entry

Tags: Esophageal Cancer, Gastric Cancer, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


February 21st, 2013

Surgery Improves Survival in Esophageal Cancer

By

Surgery after chemoradiotherapy—which is the standard of care in advanced esophageal cancer—increased overall and disease-free survival compared with chemoradiotherapy alone, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. The esophagus is a muscular tube that food and liquids pass through on their on their way to […]

View full entry

Tags: Esophageal Cancer, News, Stage IV/Recurrent Esophageal Cancer, Stages I-III Esophageal Cancer


October 5th, 2012

Iressa Improves Progression-Free Survival in Metastatic Esophageal Cancer

By

Treatment with Iressa® (gefitinib) slowed disease progression and improved quality of life in patients with metastatic esophageal cancer, according to the results of a phase III trial presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. The esophagus is a muscular tube that food and liquids pass through on […]

View full entry

Tags: Esophageal Cancer, News, Stage IV/Recurrent Esophageal Cancer


January 4th, 2008

Xeloda® and Eloxatin® Evaluated in Esophageal and Gastric Cancers

By

Xeloda® and Eloxatin® Evaluated in Esophageal and Gastric Cancers According to the results of a Phase III clinical trial published in the New England Journal of Medicine, it may be possible to replace 5-FU (5-fluorouracil) with Xeloda® (capecitabine) and to replace cisplatin (Platinol®) with Eloxatin® (oxaliplatin) in the treatment of advanced esophageal and gastric cancers. […]

View full entry

Tags: News, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer